Palvella Therapeutics (PVLA) CFO Korenberg Sells 1,000 Shares

Matthew Korenberg, the CFO and Treasurer of PVLA, sold 1,000 shares of the company on June 12, 2026. This transaction was not part of a pre-planned trading program. The shares were sold at an average price of $13.60, although the current trading price of PVLA is significantly higher at $116.51.

Insider Buying and Selling at Palvella Therapeutics, Inc.

On June 12, 2026, Matthew Korenberg sold 1,000 shares of PVLA. The sale was executed at an average price of $13.60 per share. This transaction was not pre-planned under Rule 10b5-1. In addition to Korenberg's sale, several other insiders, including John Doux, George Jenkins, Christopher Kiritsy, and Tadd Wessel, each purchased 3,000 shares on June 10, 2026.

Other Institutional Activity in PVLA

Several institutional investors have recently adjusted their positions in PVLA. Suvretta Capital Management added 261,096 shares, bringing its total to 1,153,496 shares valued at about $143.8 million. First Light Asset Management also increased its holdings by 271,617 shares, ending with 980,758 shares worth approximately $122.3 million. BVF Inc/IL grew its position by 81,980 shares, now holding 960,989 shares valued at roughly $119.8 million. Meanwhile, Frazier Life Sciences Management expanded its stake by 160,000 shares to 882,400 shares valued at $110.0 million. BlackRock, Inc. increased its holdings by 127,788 shares, reaching a total of 686,853 shares valued at around $85.6 million.

Palvella Therapeutics, Inc. Stock Down 8.5%

Shares of PVLA are currently trading near $116.51. The stock has seen significant interest from institutional investors, as reflected by recent changes in their holdings. Analyst ratings also suggest positive sentiment, with several firms maintaining a 'buy' rating.

Analysts Set New Price Targets

Analysts continue to show strong interest in PVLA. On May 21, 2026, Chardan Capital maintained its 'buy' rating with a price target of $240. Stephens & Co. initiated coverage on May 12, 2026, with a 'buy' rating and a $220 price target. Other firms like HC Wainwright & Co. and Mizuho have also maintained 'buy' ratings with targets ranging from $215 to $270.

Bottom Line

Matthew Korenberg's recent sale of PVLA shares highlights the ongoing insider activity at the company. While insider sales can be notable, they don't necessarily indicate a lack of confidence in the company's future. Institutional investors are actively trading PVLA, reflecting varying strategies and expectations. Analyst ratings suggest continued optimism, with price targets significantly above the current trading price. As always, it's important for investors to consider multiple factors and conduct their own research.